Abstract
Sanofi has entered into a global research collaboration and licensing option with Rib-X Pharmaceuticals to develop and commercialise novel classes of antibiotics resulting from Rib-X’s RX-04 programme for the treatment of drug-resistant pathogens. Sanofi will have the rights to develop multiple products from the collaboration, which will initially focus on at least four target product profiles.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
